Standards for clinical trials in male sexual dysfunctions

J Sex Med. 2010 Jan;7(1 Pt 2):414-44. doi: 10.1111/j.1743-6109.2009.01623.x.

Abstract

Introduction: Clinical trials in male sexual dysfunction (MSD) are expanding. Consequently, there is a need for consensus standards in this area.

Aim: To develop an evidence-based, state-of-the-art consensus report on standards for clinical trials in MSD.

Methods: A literature review was performed examining clinical trials in erectile dysfunction (ED), premature ejaculation (PE), delayed/absent ejaculation, libido disorders/loss of desire, hypogonadism, and Peyronie's disease, focusing on publications published in the last 20 years. This manuscript represents the opinions of eight experts from seven countries developed in a consensus process. This document was presented for peer review and debate in a public forum and revisions were made based on recommendations of chairpersons to the International Consultation on Sexual Medicine.

Main outcome measure: Expert opinion was based on the grading of evidence-based medical literature, widespread internal committee discussion, public presentation, and debate.

Results: According to experience and recent publications in dealing with clinical trials in sexual dysfunction, recommendations have been made for conducting trials in patients with ED, PE, delayed ejaculation, libido disorders, hypogonadism, and Peyronie's disease.

Conclusions: It is important that future clinical trials are conducted using standards upon which investigators can rely when reading manuscripts or conducting new trials in this field.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Ejaculation
  • Erectile Dysfunction / epidemiology*
  • Erectile Dysfunction / therapy*
  • Humans
  • Hypogonadism / epidemiology
  • Hypogonadism / therapy
  • Interpersonal Relations
  • Male
  • Penile Induration / epidemiology
  • Penile Induration / therapy
  • Phosphodiesterase Inhibitors / therapeutic use
  • Prevalence
  • Sexual Dysfunction, Physiological / epidemiology*
  • Sexual Dysfunction, Physiological / therapy*
  • Sexual Partners

Substances

  • Phosphodiesterase Inhibitors